{"gao_id": "GAO-20-594", "published": "2020-09-08T12:00:00Z", "released": "2020-10-08T08:00:00Z", "summary": "In 2017, the Food and Drug Administration created a new office within the agency to oversee its lab safety program. But, 3 years later, there are still disagreements within the FDA about the office's roles and responsibilities. Moreover, FDA's lab safety program does not include key elements of effective oversight. For example, lab safety office staff cannot inspect labs unannounced. Unannounced inspections can help to...", "title": "Laboratory Safety: FDA Should Strengthen Efforts to Provide Effective Oversight", "topics": ["Biologics", "Working capital fund", "Compliance oversight", "Pathogens", "Safety", "Health Care", "High-containment laboratories", "Biological agents", "Reorganization", "Laboratory safety", "Strategic plan"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-20-594", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-20-594-highlights.pdf"}, {"title": "Full Report (49 pages)", "url": "https://www.gao.gov/assets/gao-20-594.pdf"}, {"title": "Accessible PDF (59 pages)", "url": "https://www.gao.gov/assets/710/709288.pdf"}]}